Is Alkermes plc (ALKS) a Buy, Sell, or Hold?
Alkermes plc
NASDAQ:ALKS
$51.6 USD
-$0.27 (-0.52%)
- Volume
- 1.78M
- Average Volume
- 2.22M
- Market Capitalization
- $8.6B
- P/E Ratio
- 55.48
- Dividend Yield
- 0.00%
- Price Target
- $54.00
- Year High
- $55.67
- Year Low
- $25.17
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.27
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Richard F. Pops |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALKS |
| CUSIP | G01767105 |
| CIK | 0001520262 |
| Web | http://www.alkermes.com |
| Phone | 353 1 772 8000 |
| Currency | USD |
| Employees | 2050 |
| Country | IE |
Liquidity
| Debt-to-Equity Ratio | 0.90 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.27 |
| Quick Ratio | 1.70 |
| Cash Ratio | 0.59 |
Sales & Book Value
| Annual Sales | $1.48B |
| Price / Sales | 5.51 |
| Cash Flow | 1.33 |
| Price / Cash Flow | 38.78 |
| Price / Book | 4.90 |
Price Target and Rating
| Average Stock Price Forecast | $54.00 |
| High Stock Price Forecast | $65.00 |
| Low Stock Price Forecast | $43.00 |
| Forecast Upside/Downside | -4.44% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 29 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.43 |
| Trailing P/E Ratio | 55.48 |
| PEG Ratio | -0.98 |
| P/E Growth | -0.98 |
| Net Income | $241.66M |
| Net Margin | 9.78% |
| Pretax Margin | 13.06% |
| Return on Equity | 8.82% |
| Return on Assets | 3.59% |
Financials Score
| AltmanZ Score | 2.57 |
| Piotroski Score | 5.00 |
| Working Capital | 759.14M |
| Total Assets | 4.26B |
| Ebit | 237.2M |
| Market Cap | 8.65B |
| Total Liabilities | 2.51B |
Poll Results
About Alkermes plc (NASDAQ:ALKS) Stock
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug can ... didate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes to Report Second Quarter Financial Results on July 28, 2026
2026-07-14 16:00:00
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast.
2026-07-13 07:00:00
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline1 on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 24 of the LTE, approxim.
Biotech ETF Index Surges 10% After Rebalance
2026-06-25 11:31:47
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tells Investors
2026-06-23 21:00:00
On June 23, 2026, Alkermes PLC (ALKS) shares rose 4.3% today, bringing the current price to $48.06. Over the past week, shares increased by 9.0%, and have seen
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
2026-06-19 15:49:55
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.
2026-06-17 16:15:00
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the study's dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared to placebo on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week eight in adults with NT2 (n=.
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
2026-06-16 11:15:26
Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
2026-06-15 07:00:00
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug designations (ODD) from leading regulatory bodies in the U.S. and Europe. The U.S. Food and Drug Administration (FDA) has granted ODD to alixorexton for the treatment of IH, and the Euro.
Frequently Asked Questions
-
What is the current Alkermes plc (ALKS) stock price?
-
Alkermes plc(NASDAQ:ALKS) stock price is $51.6 in the last trading session. During the trading session, ALKS stock reached the peak price of $55.67 while $25.17 was the lowest point it dropped to. The percentage change in ALKS stock occurred in the recent session was --0.52% while the dollar amount for the price change in ALKS stock was -$-0.27.
-
ALKS's industry and sector of operation?
-
The NASDAQ listed ALKS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALKS?
-
Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations
Christian Todd Nichols | Senior Vice President & Chief Commercial Officer
Richard F. Pops | Chairman & Chief Executive Officer
Tom Skoff | SVP & Chief Information Officer
David Joseph Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary -
How many employees does ALKS have?
-
Number of ALKS employees currently stands at 2050. ALKS operates from Connaught House, Dublin, DU D04 C5Y6, IE.
-
Link for ALKS official website?
-
Official Website of ALKS is: http://www.alkermes.com
-
How do I contact ALKS?
-
ALKS could be contacted at phone #353 1 772 8000 and can also be accessed through its website. ALKS operates from Connaught House, Dublin, DU D04 C5Y6, IE.
-
How many shares of ALKS are traded daily?
-
The average number of ALKS shares traded daily for last 3 months was 2.22M.
-
What is the market cap of ALKS currently?
-
The market value of ALKS currently stands at $8.6B with its latest stock price at $51.6